The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Enhanced recovery program successfully reduced opioid use after pancreatic cancer surgery

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

By improving hospital care pathways, researchers from MD Anderson Cancer Center successfully reduced inpatient opioid use by 50% after pancreatic cancer surgery and cut the median opioid prescription volumes at discharge to zero. 

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

University of Miami’s Jashodeep Datta awarded $800K DoD grant to study pancreatic cancer

Jashodeep Datta, a researcher with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, has been awarded a grant from the U.S. Department of Defense’s Congressionally Directed Medical Research Program to target chemotherapy resistance in pancreatic cancer. The $800,000, three-year grant is the first DoD award to Sylvester to study pancreatic cancer.
Clinical Roundup

Combining immunotherapy with KRAS inhibitor eliminates advanced KRAS-mutant pancreatic cancer in preclinical models

Researchers at MD Anderson Cancer Center have uncovered a functional role for KRAS mutations in pancreatic cancer and rapidly translated these findings into a novel therapeutic approach combining a KRAS G12D inhibitor with immune checkpoint inhibitors for early- and late-stage KRAS G12D-mutant pancreatic cancer. The combination therapy led to durable tumor elimination and significantly improved survival outcomes in preclinical models, leading to the launch of a phase I clinical trial.
Clinical Roundup

Combination therapy for pancreatic cancers appears promising in platform trial

Research directed by Johns Hopkins showed that for patients with operable pancreatic cancers, a three-pronged combination immunotherapy treatment—consisting of the pancreatic cancer vaccine GVAX, the immune checkpoint therapy nivolumab and urelemab, an anti-CD137 agonist antibody treatment—is safe, increases the amount of cancer-killing immune system T cells in the tumors, and appears effective when given two weeks prior to cancer-removal surgery. A description of the work was published in Nature Communications.
Table of Contents

Login

Looking for IP Login?